EA Pharma strengthens its international presence with the acquisition of the Spanish Group DRASANVI, its fourth build-up with Motion
The French laboratory Equilibre Attitude, a reference player in Oligotherapy, food supplements and sports nutrition, today announces that it has entered into exclusive negotiations with the Spanish Group Drasanvi, to realise its first international acquisition.
Renowned for its expertise in Oligotherapy, Equilibre Attitude is a French pharmaceutical Group offering a large range of drugs and food supplements:
- Oligotherapy: drugs and food supplements formulated with oligo-elements under the brands Oligosol, Laboratoire des Granions and Oligostim;
- Well-being and health: a complete range of food supplements, with flagship products such as Duab (urinary comfort), Chondrostéo (joint care), Conceptio (fertility and pregnancy) or Veinomix (venous comfort);
- Sports nutrition: food supplements, nutritive products and athletic health care with the brands EAFit, Punch Power and Foucaud.
The Group’s products are distributed in pharmacies and parapharmacies, as well as in specialized stores and online.
EA Pharma has also recently signed a commercial partnership with Poupina brand, a long-standing range of Baby care products, ensuring the Group’s rapid penetration into this new line of products and strengthening its presence in pharmacies.
Drasanvi is a leading Spanish company in the food supplements, natural cosmetics and health nutrition sector. With more than 25 years of experience, the Group is a reference player in the field of health, beauty and wellbeing thanks to its high-quality products of natural origin. Drasanvi enjoys a unique position with a wide range of products. The company markets brands such as Super Alimentos, Collmar, Botanical bio, Vital pur, Immunol and Oseogen.
Drasanvi’s product range is based on 3 pillars: a differentiating quality, a rigorous selection of raw materials and a controlled internal production process through its industrial tool located in Leon.
“We are convinced that the combination of EA Pharma and Drasanvi will allow both companies to accelerate their development. Both groups share a common culture of developing high quality and differentiated products,” said Thierry Verne, CEO of EA Pharma.
“For Drasanvi, this combination is a big step forward in its international expansion, we will strengthen both companies, innovation and commitment to quality will continue to be our hallmarks. The entire Drasanvi family is very pleased with this new success,” declared Oscar Lopez, CEO & Founder of Drasanvi.
This first international acquisition follows the successive takeovers of Nutrivercell (2017), PunchPower (2018) and Labcatal (2020).
“We are very proud of this new step in the EA Pharma project. With the acquisition of Drasanvi, EA Pharma becomes a true European consolidation platform ideally positioned to pursue its development,” said Patrick Eisenchteter, Managing Partner at Motion Equity Partners.